Literature DB >> 25416048

Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro.

Zhonglu Yang1, Zhiyi Wu, Tao Liu, Lei Han, Chunhui Wang, Bo Yang, Fei Zheng.   

Abstract

3-Phosphoinositide-dependent protein kinase-1 (PDK1) has been reported to be closely correlated with proliferation, apoptosis and invasion of esophageal cancer cells. However, its expression pattern and clinical significance in human esophageal squamous cell carcinoma (ESCC) remain unclear. To address this problem, immunohistochemistry was performed to detect the expression and the subcellular localization of PDK1 protein in 120 paired of formalin-fixed and paraffin-embedded cancerous and adjacent non-cancerous tissues. Then, its associations with tumor progression and patients' prognosis were statistically evaluated. After that, we performed migration and invasion assays of siRNA-targeted PDK1-transfected cells in vitro. As a result, immunohistochemistry analysis showed that the PDK1 protein was expressed in cytoplasm of the carcinoma cells in ESCC tissues, but not expressed in adjacent non-cancerous tissues. Statistical analysis indicated that the expression level of PDK1 protein in ESCC tissues was significantly higher than those in adjacent non-cancerous tissues (P < 0.001). In addition, high PDK1 expression was found to be closely correlated with advanced tumor stage (P = 0.006), positive lymph node metastasis (P = 0.01) and high histological grade (P = 0.02). Moreover, survival analysis revealed that PDK1 overexpression was significantly associated with shorter overall survival (P = 0.001). The multivariate analysis further identified PDK1 expression as an independent prognostic factor for ESCC patients. In ESCC cell lines, the knockdown of PDK1 using siRNA inhibited the cell migration and invasion in vitro. These findings support that PDK1 may contribute to the aggressive progression of ESCC. Of note, PDK1 may serve as an effective prognostic marker and provide a novel therapeutic strategy against human ESCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25416048     DOI: 10.1007/s12032-014-0337-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

1.  Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Jennifer S Herrick; Roger K Wolff
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

2.  The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts.

Authors:  Joanna Zabkiewicz; Lorna Pearn; Robert K Hills; Rhys G Morgan; Alex Tonks; Alan K Burnett; Richard L Darley
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

3.  Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice.

Authors:  Jose R Bayascas; Nick R Leslie; Ramon Parsons; Stewart Fleming; Dario R Alessi
Journal:  Curr Biol       Date:  2005-10-25       Impact factor: 10.834

4.  MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway.

Authors:  Jian Zhou; Shiduo Song; Songbing He; Xinguo Zhu; Yi Zhang; Bin Yi; Bing Zhang; Gongzhao Qin; Dechun Li
Journal:  Int J Mol Med       Date:  2014-01-28       Impact factor: 4.101

5.  Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Authors:  Neil E Bhola; Maria L Freilino; Sonali C Joyce; Malabika Sen; Sufi M Thomas; Anirban Sahu; Andre Cassell; Ching-Shih Chen; Jennifer R Grandis
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

6.  Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.

Authors:  Ayaz Najafov; Natalia Shpiro; Dario R Alessi
Journal:  Biochem J       Date:  2012-12-01       Impact factor: 3.857

7.  Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer.

Authors:  Jing Yu; Kui-Sheng Chen; Ya-Nan Li; Juan Yang; Lu Zhao
Journal:  Asian Pac J Cancer Prev       Date:  2012

8.  Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.

Authors:  Koushiro Ohtsubo; Tadaaki Yamada; Lu Zhao; Tie-Feng Jin; Shinji Takeuchi; Hisatsugu Mouri; Kaname Yamashita; Kazuo Yasumoto; Naoya Fujita; Hirohisa Kitagawa; Tetsuo Ohta; Hiroko Ikeda; Seiji Yano
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

Review 9.  Neoadjuvant treatment for esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Naoya Yoshida; Hideo Baba
Journal:  World J Gastrointest Oncol       Date:  2014-05-15

10.  Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha.

Authors:  Xiao Zeng; Hangmin Xu; Robert I Glazer
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  7 in total

Review 1.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

2.  Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis.

Authors:  Marie C Matrka; Miki Watanabe; Ranjithmenon Muraleedharan; Paul F Lambert; Andrew N Lane; Lindsey E Romick-Rosendale; Susanne I Wells
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

3.  Identification of crucial miRNAs and genes in esophageal squamous cell carcinoma by miRNA-mRNA integrated analysis.

Authors:  Xiaowu Zhong; Guangcheng Huang; Qiang Ma; Hebin Liao; Chang Liu; Wenjie Pu; Lei Xu; Yan Cai; Xiaolan Guo
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.

Authors:  Shin Pai; Vijesh Kumar Yadav; Kuang-Tai Kuo; Narpati Wesa Pikatan; Chun-Shu Lin; Ming-Hsien Chien; Wei-Hwa Lee; Michael Hsiao; Shao-Chih Chiu; Chi-Tai Yeh; Jo-Ting Tsai
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 5.  Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.

Authors:  Laura Di Blasio; Paolo A Gagliardi; Alberto Puliafito; Luca Primo
Journal:  Cancers (Basel)       Date:  2017-03-11       Impact factor: 6.639

6.  Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro.

Authors:  Chengjuan Zhang; Junxia Zhang; Qiong Wu; Benling Xu; Guoguo Jin; Yan Qiao; Simin Zhao; Yang Yang; Jinwen Shang; Xiaofang Li; Kangdong Liu
Journal:  Cancer Cell Int       Date:  2019-12-19       Impact factor: 5.722

7.  Phosphoinositide-dependent Kinase-1 (PDPK1) regulates serum/glucocorticoid-regulated Kinase 3 (SGK3) for prostate cancer cell survival.

Authors:  Geetha Nalairndran; Azad Hassan Abdul Razack; Chun-Wai Mai; Felicia Fei-Lei Chung; Kok-Keong Chan; Ling-Wei Hii; Wei-Meng Lim; Ivy Chung; Chee-Onn Leong
Journal:  J Cell Mol Med       Date:  2020-09-14       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.